On Wednesday, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), subtract -1.09% and closed at $22.69 in the last trading session. The last trading range of the stock ranges between $22.55 and $23.36. The company’s Market capitalization is $7.52 Billion with the total Outstanding Shares of 341.19 million. During the 52-week trading session the minimum price at which share price traded, registered at $18.55 and reached to max level of $179.83. Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) recently declared that Louis W. Yu, Ph.D. has been designated to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016.
Dr. Yu will report to Joseph C. Papa, Chairman and CEO of Valeant. As a new member of Valeant’s Executive Committee, Dr. Yu will oversee all aspects of quality and regulatory compliance for all of Valeant’s global businesses and operating sites.
Dr. Yu joins Valeant with more than 30 years of leadership experience in the Quality and R&D functions of generic and branded pharmaceutical companies. He was Executive Vice President, Global Quality & Compliance at The Perrigo Company from November 2006 to January 2016, where he was responsible for planned leadership and regulatory compliance in addition to the global patient safety/medical affairs departments. He also served between May and September 2016 as the Senior Vice President, Global Quality and Compliance at AMRI, a contract development and manufacturing organization (CDMO) company.
“Delivering quality products leads to quality health outcomes, and that is what we are focused on at Valeant,” said Joseph C. Papa, chief executive officer of Valeant. “Dr. Louis Yu is a great addition to our organization, and we are delighted to bring him into the company in the important new role of Chief Quality Officer. Dr. Yu’s deep quality leadership experience at a number of branded and generic pharmaceutical companies gives him a deep understanding of what our customers and regulators need, and I look forward to working closely with him.”
Huntington Bancshares Incorporated (NASDAQ:HBAN), dropped -0.50% and closed at $9.97 in the last trading session. The last trading range of the stock ranges between $9.95 and $10.09. The company’s Market capitalization is $7.86 Billion with the total Outstanding Shares of 799.15 million. Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The companys Retail and Business Banking segment offers financial products and services, counting checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, and foreign exchange and treasury administration services. Its Commercial Banking segment provides corporate risk administration and institutional sales, trading, and underwriting services; commercial property and casualty, employee benefits, personal lines, life and disability, and specialty lines of insurance; and brokerage and agency services for residential and commercial title insurance, in addition to excess and surplus product lines of insurance. The companys Automobile Finance and Commercial Real Estate segment offers financing for the purchase of vehicles; financing the acquisition of new and used vehicle inventory of franchised automotive dealerships; and financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers. Its Regional Banking and The Huntington Private Client Group segment provides deposits, lending, and other banking services; wealth administration services, and retirement plan and corporate trust services; and brokerage, annuities, advisory, and other investment products. The companys Home Lending segment offers consumer loans and mortgages.